|View printer-friendly version|
|HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference|
FRAMINGHAM, Mass. and SYDNEY, Dec. 2, 2010 /PRNewswire via COMTEX/ --
HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Canaccord Genuity Cardio/Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time). The conference is being held December 7-8, 2010 at the Nikko Hotel in San Francisco.
A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will also be available shortly after the presentation time for a period of 15 days.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(R) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy. For additional information, please visit www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000(R) and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
SOURCE HeartWare International, Inc.